{"name":"Fidia Farmaceutici s.p.a.","slug":"fidia-farmaceutici-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Itami","genericName":"Itami","slug":"itami","indication":"Other","status":"marketed"},{"name":"Liposom Forte","genericName":"Liposom Forte","slug":"liposom-forte","indication":"Other","status":"marketed"},{"name":"Tricortin 1000","genericName":"Tricortin 1000","slug":"tricortin-1000","indication":"Adrenocortical insufficiency","status":"marketed"}]}],"pipeline":[{"name":"Itami","genericName":"Itami","slug":"itami","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Liposom Forte","genericName":"Liposom Forte","slug":"liposom-forte","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tricortin 1000","genericName":"Tricortin 1000","slug":"tricortin-1000","phase":"marketed","mechanism":"Tricortin 1000 is a corticotropin (ACTH) analog that stimulates the adrenal cortex to produce endogenous corticosteroids.","indications":["Adrenocortical insufficiency","Infantile spasms (West syndrome)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNUnNqbjk4bnNseEY5eExDVWtXbGo1UE01aUo1SW9PRWU4UmdJY0h5TUFwN0pycHRuUnFRRmxrWTRfWmROUFlySGdZQkRFcHRFVUZ4ZkJTOHA3Z2E5STJMaVhIMG1ySGRKMEdBSHZXaE1DcUQ0OGwtWDNHWms1NEkwckpQVmE4azV3bnhQRnRGdmFtbGtnQ096U001c9IBoAFBVV95cUxNWTRNc1B5bWdWY3I0c1RBZ3ZWVXR0MENHN3VNZzRRZi1qUFppTWpvNW9TMzhGcEhueWxyV2tMODQwRll3ek96eHlGZWdhVjNDYk9vVlRNVm9adllNX0ozR21VRFI3cGllX2ZaV1FOWXE0WVZEOF9sc1JZdFEtSHd4cVo0Nzd6ZVJXZ0Y2Sm51WTVPLVl6Y2JfSU1KbERqR29l?oc=5","date":"2025-09-01","type":"pipeline","source":"The Romania Journal","summary":"Competition Council Clears Fidia’s Takeover of Meditrina - The Romania Journal","headline":"Competition Council Clears Fidia’s Takeover of Meditrina","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQTWhjdHhadzg4TmIzdXdIYWZFajFhekVXd3NGN3Z5aVJkY2NuOTJ5TXRUdWtadHJkRUprQTRoamIzVnFNeXZiODVMWjA4LVBDR3Zmc1E4UG1pbVlZOC03NkxuQldyRU44enBxYnhhM2otMVVBamdNU1NRSVFJNzJUQTgyT3lfMEx1S2lDUmdlS1gtUW0wNjZUd3JHeVMyaGV5THM1Tk1GQkdzS0pMbkJGN1lwd3FIVmlmbzA5RUhhaE1xWnZJM1JLZzBKQ0dSaGVHRml4Q2tJZXFFTllPSmNkM3NpbklEdXhGTldDTzBqVFlHdmtZV1ZxQnUxYVNrTXB1b2ZHaDhsbDBVbDg?oc=5","date":"2025-07-25","type":"pipeline","source":"Business Review","summary":"EY Romania provided tax advisory services to Fidia Farmaceutici in acquiring majority stake in Meditrina Pharmaceuticals - Business Review","headline":"EY Romania provided tax advisory services to Fidia Farmaceutici in acquiring majority stake in Meditrina Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9kSVVPc3M5VjM0ai0zN18ybTVTZTRzT0tIN1FOWG0tLVZzZ21YS1RZdW1abkJYbG9HaWVxUUw3cWtrZUQ1RjhvbkVmNE1mYVpHdkE1SDRPT1FlUTRTcUhVNFVsMmZtb1dyeFU2VmVUbw?oc=5","date":"2023-12-08","type":"regulatory","source":"Straits Research","summary":"Viscosupplementation Market Size, Share & Demand | 2033 - Straits Research","headline":"Viscosupplementation Market Size, Share & Demand | 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBCWndpeEV3akRBcER4S2FjQnF4YWx3NVh3TFo3bGtodXlNdVM4a1hKZFFwOWpFM0ZINC1QMnpCZzJPQlh6U0dSbC1KdWhWVVNidzlQWXNPQUE1VnhWdHVmSUdkUktwTFVTcXN0V1JJZ21Edw?oc=5","date":"2022-08-23","type":"pipeline","source":"Market.us","summary":"Knee Hyaluronic Acid Injections Маrkеt - Market.us","headline":"Knee Hyaluronic Acid Injections Маrkеt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNOUxpdVVOQ2x1elV4V1RHcURucDM0by14YWFKY09HMUdNa0ZGS0pxU0lpb2pOdFBfaWR1SmlDcHd0RWZ4YTJfYldtZ0tzV2c0RjgyLW5UV0R1Y0hLS3VZQXZmd29nSGNsYW1lRGZmVHh1ckhuX1hZMUFqeFQxYVltUXdCbm4tQ3FrMHNNVHk5cVUwWHdDd1UwYTl6d1hEV2ti?oc=5","date":"2021-10-15","type":"pipeline","source":"grandviewresearch.com","summary":"Sodium Hyaluronate-based Products Market Report, 2030 - grandviewresearch.com","headline":"Sodium Hyaluronate-based Products Market Report, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOcFlxY2o0a3puMnJrRkdRUzcyXzEyLXBEWTV3Y0xsa2RITk1uUWd6dGhBY2xLbTZZSm16QlBYSVNpOVg0dkd6a25uN0JJWkhYanplb0RqU2xhTXNLZkNwVk1vcncxTV9JZFBrdVRSbFhwQmVtNFF4X3pPeXhmc29uNWhrOHliRlE?oc=5","date":"2021-03-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"Sanofi to divest anti-inflammatory drug portfolio to Fidia Farmaceutici - Pharmaceutical Technology","headline":"Sanofi to divest anti-inflammatory drug portfolio to Fidia Farmaceutici","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxPRU41YlpjRTY0TjFHV2dNQXlyNEdWLVRMcEdtdWxuY2Y3cTRSazd4VmxTYmU4MHhvdDBKdV9RSUxSOVJzLVItTDluRzlVSEthaHQ1WmpYaU9VeHBmcy12MTZXSGhHNkx4dHhMcHc2M2NsbllWd2R6RjVnbnVfR1RWOGlQTnRydnVCRUdUdUloTDNWeFRlN1kxTVYzNFRVeG9KLXJUdHZFYjMwMXdUWXhyaEhPbllodkk3YlZLV1FnSVZDTzZvMHU5OElqdy16TDhYM3hmaEtlYXVDSUJONHEybHcydFdEbGUxSUZsUUl5MDBFemFhQWNBLTB3N1RUWmFER2FZcy1WdEVlamt1R3M3YlVrdU1wX0c3THJObVk4WFg0M2ZwX1VnYmd3Uno3dXVRakJwMExzcHQ?oc=5","date":"2021-03-23","type":"pipeline","source":"PR Newswire","summary":"Fidia Farmaceutici Continues On Its Growth Path: Fidia Signed A Binding Agreement With Sanofi For The Acquisition Of A Portfolio Of Anti-inflammatory Drugs - PR Newswire","headline":"Fidia Farmaceutici Continues On Its Growth Path: Fidia Signed A Binding Agreement With Sanofi For The Acquisition Of A P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOSFN0Y1B2MzR3S182ek9IMWl4b0dnMGhqNXQ3dUhxZ21qWldvclJveEl3RTdrMXhSNjA4bGRuQlVCZi1fazZQLWVJY0hKYUE1R290eWZHLVR0b3dPekFuVzRkWm5lVDVmZnY5ZHJqa2ZnMU1nTHFMQVByMUdEcWF2Znp5VFd0eTQyMUVyYms0VEtZWlJ0dG1hRU5neHNqallKX0cxdWdxZnB2ekpIa1lmamNLeXhRZmswRFc0UTZrRWluVnFRRkNaaHFWX2pHUjJG?oc=5","date":"2015-07-02","type":"pipeline","source":"NTB Kommunikasjon","summary":"Fidia Farmaceutici S.p.a. Enters the Italian Pediatric Market Segment - NTB Kommunikasjon","headline":"Fidia Farmaceutici S.p.a. Enters the Italian Pediatric Market Segment","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}